Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06431750

Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis

Official title: Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis (Toddler)

Key Details

Gender

All

Age Range

6 Years - 18 Years

Study Type

OBSERVATIONAL

Enrollment

150

Start Date

2025-04-30

Completion Date

2028-08-30

Last Updated

2025-01-14

Healthy Volunteers

Conditions

Juvenile Idiopathic Arthritis

Interventions

OTHER

Secukinumab

This is an observational study, there is no treatment allocation.

Inclusion Criteria: 1. Written informed consent and legal representative's permission for study participation obtained prior to beginning of participation in the study. 2. Age ≥6 to \<18 years old. 3. Recognized physician diagnosis of active ERA or jPsA: * ERA per ILAR criteria: * Peripheral arthritis and enthesitis, or * Arthritis or enthesitis, plus ≥ 3 months of inflammatory back pain and sacroiliitis on imaging, or * Arthritis or enthesitis plus 2 of the following: sacroiliac joint tenderness; inflammatory back pain; presence of HLA-B27 antigen; acute (symptomatic) anterior uveitis; and history of a spondyloarthritis in a first-degree relative. * jPsA per ILAR criteria * Arthritis and psoriasis, or * arthritis and at least 2 of the following: * Dactylitis * Nail pitting or onycholysis * Psoriasis in a first-degree relative. 4. Patient was prescribed with secukinumab within 4-8 weeks before inclusion. 5. Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of this non-interventional study conduct. 6. The Purified Protein Derivative (PPD) Skin Test for Tuberculosis and/or Negative T-SPOT test and/or TB-feron test before secukinumab treatment and every 6 months. Exclusion Criteria: 1. Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex). 2. Chronic recurrent infections. 3. Clinically significant infection exacerbation, including active tuberculosis. 4. Age \<6 years or ≥18 years. 5. Pregnancy and breastfeeding. 6. Patients participating in parallel in an interventional clinical trial. 7. Patients participating in parallel in other Novartis-sponsored non-interventional study generating primary data for secukinumab. 8. Patients within the safety follow-up phase of interventional study. 9. Active inflammatory bowel disease at inclusion. 10. Patients who received any vaccine within 4 weeks prior to secukinumab initiation. 11. Any medical or psychological condition in the investigator's opinion which may prevent the study participation. 12. Concomitant conditions (Candida infections, other infections, inflammatory bowel disease \[IBD\], uveitis, skin and nail psoriasis for ERA patients, hepatitis B, hepatitis C, tuberculosis).